top of page

Eyes on Pharma
Check-out What Intel Caught our Eye


Eyes on Firms Executing Strategic Plans
We've had Eyes on several firms that are actively executing on their strategic plans to ensure competitiveness in their markets. Take a look at how BioNTech, Novo Nordisk, and Merck are adapting to changing markets and technologies.

Jana Chisholm
3 days ago7 min read


Eye's on BioPharma Strategies
This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

Jana Chisholm
Jun 107 min read


Eyes on BioPharma & Tariffs
We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

Jana Chisholm
May 2710 min read


Eyes on a 23andMe & Regeneron Deal
Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.
jroele
May 193 min read


Eyes on BioPharma News
We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

Jana Chisholm
May 1414 min read


Eyes on - 23andMe
23andMe files for Chapter 11 bankruptcy and seeks a court-managed sale, co-founder and CEO Anne Wojcicki will step down

Jana Chisholm
May 52 min read
bottom of page